Prior Authorization Burden on the Use of LCP-Tacrolimus in Abdominal Solid Organ Transplant Recipients

Abstract

Get full access to this article

View all access options for this article.

References

Jorgenson

Descourouez

Brady

, et al. Alternatives to immediate release tacrolimus in solid organ transplant recipients: when the gold standard is in short supply. Clin Transplant. 2020;34:e13903. doi:10.1111/ctr.13903

Budde

Bunnapradist

Grinyo

, et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of phase III, double-blind, randomized trial. Am J Transplant. 2014;14:2796-2806. doi:10.1111/ajt.12955

Langone

Steinberg

Gedaly

, et al. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant. 2015;29:796-805. doi:10.1111/ctr.12581

Trofe-Clark

Brennan

West-Thielke

, et al. Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients. Am J Kidney Dis. 2018;71:315-326. doi:10.1053/j.ajkd.2017.07.018

Resneck

Jr.

Refocusing medication prior authorization on its intended purpose. JAMA. 2020;323:703-704. doi:10.1001/jama.2019.21428